Inpharma Weekly

, Volume 1048, Issue 1, pp 15–16 | Cite as

Improving therapy for prostate cancer

  • Lawrence Prescott
Newsletter Article


Patients with locally advanced prostate cancer have a greater chance of survival if they receive goserelin plus radiotherapy, rather than radiotherapy alone, according to the results of a study presented at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO) [ Philadelphia, US; May 1996 ]. The study provides the first clinical evidence of a survival benefit with this combination treatment. Also at the conference, the latest data were presented from a study comparing bicalutamide with flutamide, and from a trial investigating the role of antineoplastic chemotherapy in hormone-refractory prostate cancer.


Prostate Cancer Hydrocortisone Mitoxantrone Flutamide Advanced Prostate Cancer 

Copyright information

© Adis International Ltd 1996

Authors and Affiliations

  • Lawrence Prescott

There are no affiliations available

Personalised recommendations